ASCO
Audio Journal of Oncology in Advance -July 15th, 2007 - reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007">
Audio Journal of Oncology in Advance -July 15th, 2007 - reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007
Volker Diehl
George Canellos
Hodgkin’s Disease: 10-Year Results Show Further Benefit From Escalated BEACOPP Therapy
REFERENCE: Abstract 8015, ASCO Annual Meeting Chicago June 1-5, 2007
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at the ASCO Annual Meeting have given further support to the use of an escalated BEACOPP regimen in patients with Hodgkin’s disease. Volker Diehl, of the University of Cologne, discussed his latest data with George Canellos, of the Dana-Farber Cancer Institute in Boston, and Peter Goodwin.
VOLKER DIEHL, University of Cologne
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Long-term results presented at the ASCO Annual Meeting have given further support to the use of an escalated BEACOPP regimen in patients with Hodgkin’s disease. Volker Diehl, of the University of Cologne, discussed his latest data with George Canellos, of the Dana-Farber Cancer Institute in Boston, and Peter Goodwin.
Sandra Horning
Less Radiation Is Significantly Better for Patients With Favorable Hodgkin’s Disease
REFERENCE: Abstract 8014, ASCO Annual Meeting Chicago June 1-5, 2007
SANDRA HORNING, Stanford University
Less aggressive radiotherapy when combined with chemotherapy has proven superior to the use of extended field radiotherapy for patients with favorable prognosis Hodgkin’s disease. This finding from long-term follow-up of mature data from a Stanford University study was presented at the 2007 ASCO Annual Meeting in Chicago. After her talk in the lymphoma session, Sandra Horning talked with Sarah Maxwell about her group’s latest results.
SANDRA HORNING, Stanford University
Less aggressive radiotherapy when combined with chemotherapy has proven superior to the use of extended field radiotherapy for patients with favorable prognosis Hodgkin’s disease. This finding from long-term follow-up of mature data from a Stanford University study was presented at the 2007 ASCO Annual Meeting in Chicago. After her talk in the lymphoma session, Sandra Horning talked with Sarah Maxwell about her group’s latest results.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Audio Journal of Oncology in Advance -July 1st, 2007 - reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007">Audio Journal of Oncology in Advance -July 1st, 2007 - reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007
Christian Manegold
Roy Herbst
More Support for Bevacizumab in Advanced Lung Cancer
REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab to chemotherapy for patients with advanced non-small cell lung cancer was further underlined by a phase III trial presented at ASCO. A European study tested two doses of the targeted agent with or without cisplatin plus gemcitabine chemotherapy. Derek Thorne heard the results from Christian Manegold of the University of Heidelberg.
CHRISTIAN MANEGOLD, Heidelberg University, Mannheim
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
The benefit of adding bevacizumab to chemotherapy for patients with advanced non-small cell lung cancer was further underlined by a phase III trial presented at ASCO. A European study tested two doses of the targeted agent with or without cisplatin plus gemcitabine chemotherapy. Derek Thorne heard the results from Christian Manegold of the University of Heidelberg.
David Baker
Reduced Chemotherapy: Same Benefit in Pediatric Intermediate Risk Neuroblastoma
REFERENCE: Abstract 9504, ASCO Annual Meeting Chicago June 1-5, 2007
DAVID BAKER, Princess Margaret Hospital, Perth
A phase III study of pediatric patients with neuroblastoma has shown that chemotherapy doses can be reduced whilst maintaining the typical high survival rates of standard dose radiotherapy. Sarah Maxwell talked with investigator David Baker during the ASCO conference.
DAVID BAKER, Princess Margaret Hospital, Perth
A phase III study of pediatric patients with neuroblastoma has shown that chemotherapy doses can be reduced whilst maintaining the typical high survival rates of standard dose radiotherapy. Sarah Maxwell talked with investigator David Baker during the ASCO conference.
Robert Mayer
Oral Agent Benefits Patients with Advanced Gastric Cancer
REFERENCE: Abstracts 4513 and 4514, ASCO Annual Meeting Chicago June 1-5, 2007
ROBERT MAYER, Dana-Farber Cancer Institute, Boston
The oral pro-drug known as S-1 has been shown in two Japanese studies to bring survival benefit to patients with advanced gastric cancer. During the ASCO meeting Peter Goodwin asked Robert Mayer for the details and for his assessment of the importance of these new data.
ROBERT MAYER, Dana-Farber Cancer Institute, Boston
The oral pro-drug known as S-1 has been shown in two Japanese studies to bring survival benefit to patients with advanced gastric cancer. During the ASCO meeting Peter Goodwin asked Robert Mayer for the details and for his assessment of the importance of these new data.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Audio Journal of Oncology in Advance - June 15th, 2007 - reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007">Audio Journal of Oncology in Advance - June 15th, 2007 - reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007
Christiane Kuhl
Julie Gralow
MRI Better Than Mammography for Detecting High-Grade Ductal Carcinoma In Situ?
REFERENCE: 1504, ASCO Annual Meeting Chicago June 1-5, 2007
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting in Chicago heard findings from Germany that suggested MRI was better than mammography for the detection of ductal carcinoma in situ, or preinvasive breast cancer. Derek Thorne spoke to Christiane Kuhl, from the University of Bonn, about her team’s provocative data, while Julie Gralow of the University of Washington commented on how this study could affect clinical practice.
CHRISTIANE KUHL, University of Bonn, Germany
COMMENT: JULIE GRALOW, University of Washington, Seattle
The ASCO meeting in Chicago heard findings from Germany that suggested MRI was better than mammography for the detection of ductal carcinoma in situ, or preinvasive breast cancer. Derek Thorne spoke to Christiane Kuhl, from the University of Bonn, about her team’s provocative data, while Julie Gralow of the University of Washington commented on how this study could affect clinical practice.
Priya Rastogi
No Increase in Time of Cardiac Toxicity From Trastuzumab
REFERENCE: LBA 513, ASCO Annual Meeting Chicago June 1-5, 2007
PRIYA RASTOGI, University of Pittsburgh
COMMENT: JULIE GRALOW, University of Washington, Seattle
The latest data from the large NSABP B-31 trial, which looked at trastuzumab in breast cancer, have provided some reassurance that the drug’s cardiac toxicity does not continue to grow over time. Priya Rastogi of the University of Pittsburgh School of Medicine told Derek Thorne about the findings, and she also explained her group’s new model, which could help doctors assess the risk to patients in this situation. Julie Gralow commented on her findings.
PRIYA RASTOGI, University of Pittsburgh
COMMENT: JULIE GRALOW, University of Washington, Seattle
The latest data from the large NSABP B-31 trial, which looked at trastuzumab in breast cancer, have provided some reassurance that the drug’s cardiac toxicity does not continue to grow over time. Priya Rastogi of the University of Pittsburgh School of Medicine told Derek Thorne about the findings, and she also explained her group’s new model, which could help doctors assess the risk to patients in this situation. Julie Gralow commented on her findings.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Annual Meeting Daily News Podcasts - June 5th, 2007">Annual Meeting Daily News Podcasts - June 5th, 2007
Aimery de Gramont
Robert Mayer
MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer
REFERENCE: 4007, ASCO Annual Meeting Chicago June 1-5, 2007
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
After six years of study the MOSAIC study of adjuvant therapy in colorectal cancer has confirmed a survival advantage for patients with stage III disease given oxaliplatin in addition to standard 5 fluoruracyl/leucovorin when compared with those who received the standard regimen alone. Oxaliplatin also improved progression free survival in patients with Stage II disease. These results were presented to the ASCO meeting by Aimery de Gramont, who discussed them with Peter Goodwin.
AIMERY DE GRAMONT, St Antoine Hospital, Paris
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
After six years of study the MOSAIC study of adjuvant therapy in colorectal cancer has confirmed a survival advantage for patients with stage III disease given oxaliplatin in addition to standard 5 fluoruracyl/leucovorin when compared with those who received the standard regimen alone. Oxaliplatin also improved progression free survival in patients with Stage II disease. These results were presented to the ASCO meeting by Aimery de Gramont, who discussed them with Peter Goodwin.
Ronald Bukowski
Sorafenib for Patients with Advanced Refractory Renal Cell Carcinoma: TARGET Study Results
REFERENCE: ABSTRACT 5023, ASCO Annual Meeting Chicago June 1-5, 2007
RONALD BUKOWSKI, Cleveland Clinic OH
Sorafenib has been used after the failure of first line treatment among patients with advanced renal cell carcinoma. Ronald Bukowski presented findings showing a doubling of progression free survival. He talked about the study in Chicago with Peter Goodwin.
RONALD BUKOWSKI, Cleveland Clinic OH
Sorafenib has been used after the failure of first line treatment among patients with advanced renal cell carcinoma. Ronald Bukowski presented findings showing a doubling of progression free survival. He talked about the study in Chicago with Peter Goodwin.
Ezra Cohen
Axitinib: New Therapy for Thyroid Cancer?
REFERENCE: ABSTRACT 8011, ASCO Annual Meeting Chicago June 1-5, 2007
EZRA COHEN, University of Chicago
A new drug which inhibits receptors of vascular endothelial growth factor, or VEGF, has shown antitumor activity in patients with advanced thyroid cancer: possibly ending a 30-year wait for effective new therapies for this cancer. Derek Thorne heard about phase II study results from Ezra Cohen.
EZRA COHEN, University of Chicago
A new drug which inhibits receptors of vascular endothelial growth factor, or VEGF, has shown antitumor activity in patients with advanced thyroid cancer: possibly ending a 30-year wait for effective new therapies for this cancer. Derek Thorne heard about phase II study results from Ezra Cohen.
To listen this episode please go to 2007 ASCO Annual Meeting Daily News Podcasts.
Annual Meeting Daily News Podcasts - June 4th, 2007">Annual Meeting Daily News Podcasts - June 4th, 2007
Josep Llovet
Robert Mayer
Sorafenib The ‘New Standard’ for Advanced Liver Cancer
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
Sorafenib could become the very first standard first-line systemic treatment to be recommended for patients with advanced liver cancer, according to conclusions from phase III study data unveiled at ASCO. Derek Thorne got more on this randomized trial from Josep Llovet, of the IDIBAPS Hospital Clinic in Barcelona, and the Mount Sinai School of Medicine in New York, while Robert Mayer, of the Dana-Farber Cancer Institute in Boston, provided comment.
JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
COMMENT: ROBERT MAYER, Dana-Farber Cancer Institute, Boston
Sorafenib could become the very first standard first-line systemic treatment to be recommended for patients with advanced liver cancer, according to conclusions from phase III study data unveiled at ASCO. Derek Thorne got more on this randomized trial from Josep Llovet, of the IDIBAPS Hospital Clinic in Barcelona, and the Mount Sinai School of Medicine in New York, while Robert Mayer, of the Dana-Farber Cancer Institute in Boston, provided comment.
Eric Van Cutsem
William Blackstock
First Line Cetuximab Added to FOLFIRI Prolongs Progression Free Survival in Patients with Metastatic Colorectal Cancer
REFERENCE: ABSTRACT 4000, ASCO Annual Meeting Chicago June 1-5, 2007
ERIC VAN CUTSEM, University Hospital Gasthuisberg, Leuven, Belgium
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
A new first-line option for patients with metastatic colorectal cancer prolongs progression free survival. Phase III results from the CRYSTAL trial were presented to the ASCO meeting in Chicago and show that cetuximab in combination with FOLFIRI can reduce the risk of progression by 15 per cent. Eric Van Cutsem told Sarah Maxwell more. William Blackstock added his thoughts about the clinical implications.
ERIC VAN CUTSEM, University Hospital Gasthuisberg, Leuven, Belgium
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
A new first-line option for patients with metastatic colorectal cancer prolongs progression free survival. Phase III results from the CRYSTAL trial were presented to the ASCO meeting in Chicago and show that cetuximab in combination with FOLFIRI can reduce the risk of progression by 15 per cent. Eric Van Cutsem told Sarah Maxwell more. William Blackstock added his thoughts about the clinical implications.
Bernard Nordlinger
William Blackstock
Chemotherapy with Surgery Provides Benefit for Patients with Colorectal Cancer Liver Metastases
REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
BERNARD NORDLINGER, Hôpital Ambroise Paré, Paris
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
Patients with colorectal cancer patients who have resectable liver metastases could benefit from chemotherapy before and after their surgery. That’s according to a study presented in Chicago by Bernard Nordlinger of the Hôpital Ambroise Paré in Paris. Derek Thorne talked to him about the trial’s results, and how these could affect clinical practice.
BERNARD NORDLINGER, Hôpital Ambroise Paré, Paris
COMMENT: WILLIAM BLACKSTOCK, Wake Forest University NC
Patients with colorectal cancer patients who have resectable liver metastases could benefit from chemotherapy before and after their surgery. That’s according to a study presented in Chicago by Bernard Nordlinger of the Hôpital Ambroise Paré in Paris. Derek Thorne talked to him about the trial’s results, and how these could affect clinical practice.
Vincent Rajkumar
Low Dose Dexamethasone with Lenalidomide Gives Benefit to Patients with Multiple Myeloma
REFERENCE: ABSTRACT LBA 8025, ASCO Annual Meeting Chicago June 1-5, 2007
Vincent Rajkumar, Mayo Clinic, Minnesota
A study in newly diagnosed myeloma, which compared lenalidomide plus high- or low-dose dexamethasone, has shown that the lower dose gives a better outcome. Vincent Rajkumar of the Mayo Clinic in Minnesota discussed his study with Sarah Maxwell.
Vincent Rajkumar, Mayo Clinic, Minnesota
A study in newly diagnosed myeloma, which compared lenalidomide plus high- or low-dose dexamethasone, has shown that the lower dose gives a better outcome. Vincent Rajkumar of the Mayo Clinic in Minnesota discussed his study with Sarah Maxwell.
Sandra Horning
Maintenance Rituximab Improves Outcomes After CHOP in Large B-Cell Lymphoma
REFERENCE: ABSTRACT 8011, ASCO Annual Meeting Chicago June 1-5, 2007
Sandra Horning, Stanford University, California
Maintenance rituximab after CHOP chemotherapy has been shown to extend time to treatment failure in older patients with diffuse large B-cell lymphoma. This finding is from an intergroup update that looked at 350 patients and compared maintenance rituximab to observation after R-CHOP or CHOP. Co-author Sandra Horning from Stanford University Medical Center spoke with Sarah Maxwell at the ASCO meeting in Chicago.
Sandra Horning, Stanford University, California
Maintenance rituximab after CHOP chemotherapy has been shown to extend time to treatment failure in older patients with diffuse large B-cell lymphoma. This finding is from an intergroup update that looked at 350 patients and compared maintenance rituximab to observation after R-CHOP or CHOP. Co-author Sandra Horning from Stanford University Medical Center spoke with Sarah Maxwell at the ASCO meeting in Chicago.
To listen this episode please go to 2007 ASCO Annual Meeting Daily News Podcasts.
Annual Meeting Daily News Podcasts - June 3rd, 2007">Annual Meeting Daily News Podcasts - June 3rd, 2007
Bernard Escudier
Dean Bajorin
Bevacizumab in Advanced Kidney Cancer: Another Treatment Gives Benefit in First Line
REFERENCE: ABSTRACT 3, ASCO Annual Meeting Chicago June 1-5, 2007
BERNARD ESCUDIER, Gustave Roussy Institute, Villejuif
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Doctors can now use bevacizumab for first line therapy in advanced kidney cancer. That’s according to Bernard Escudier of the Gustave Roussy Institute, who presented phase III data at ASCO. But since the drug was tested against interferon, how might it compare with sunitinib, another targeted therapy that received a ringing endorsement at last year’s annual meeting? Peter Goodwin found out more in Chicago.
BERNARD ESCUDIER, Gustave Roussy Institute, Villejuif
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Doctors can now use bevacizumab for first line therapy in advanced kidney cancer. That’s according to Bernard Escudier of the Gustave Roussy Institute, who presented phase III data at ASCO. But since the drug was tested against interferon, how might it compare with sunitinib, another targeted therapy that received a ringing endorsement at last year’s annual meeting? Peter Goodwin found out more in Chicago.
Oyvind Bruland
Benefit from Radium-223 in Hormone Refractory Prostate Cancer?
REFERENCE: ABSTRACT 5071, ASCO Annual Meeting Chicago June 1-5, 2007
OYVIND BRULAND, The Norwegian Radium Hospital, Oslo
A novel treatment involving a bone-seeking radionuclide has shown promising results in a randomised phase II trial for men with hormone refractory prostate cancer and bone metastases. Sarah Maxwell found out more from Oyvind Bruland of the Norwegian Radium Hospital in Oslo.
OYVIND BRULAND, The Norwegian Radium Hospital, Oslo
A novel treatment involving a bone-seeking radionuclide has shown promising results in a randomised phase II trial for men with hormone refractory prostate cancer and bone metastases. Sarah Maxwell found out more from Oyvind Bruland of the Norwegian Radium Hospital in Oslo.
Jan Vermorken
Roy Herbst
Cetuximab Up-Front Significantly Increases Survival in Head and Neck Cancer
REFERENCE: ABSTRACT Head and Neck Cancer Session, ASCO Annual Meeting Chicago June 1-5, 2007
JAN VERMORKEN, University Hospital Antwerp
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
Patients with head and neck squamous cell carcinoma who receive cetuximab in addition to their platinum based chemotherapy have a clear survival advantage. This was the headline result coming out of the EXTREME trial announced to the ASCO meeting in Chicago. Sarah Maxwell heard more from chief author Jan Vermorken of the University of Antwerp.
JAN VERMORKEN, University Hospital Antwerp
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
Patients with head and neck squamous cell carcinoma who receive cetuximab in addition to their platinum based chemotherapy have a clear survival advantage. This was the headline result coming out of the EXTREME trial announced to the ASCO meeting in Chicago. Sarah Maxwell heard more from chief author Jan Vermorken of the University of Antwerp.
Wendy Wahnefried
Bruce Cheson
Can Flaxseed Slow Prostate Cancer Growth?
REFERENCE: ABSTRACT 1510, ASCO Annual Meeting Chicago June 1-5, 2007
WENDY DENMARK-WAHNEFRIED, Duke University, Durham
COMMENT: BRUCE CHESON, Georgetown University, Washington DC
Flaxseed, a dietary supplement rich in lignan and omega-3 fatty acids, could help slow down the growth of prostate tumors. This came out of a phase II study presented at ASCO by Wendy Demark-Wahnefried of Duke University Medical Center in Durham, North Carolina. Derek Thorne heard more details from her in Chicago.
WENDY DENMARK-WAHNEFRIED, Duke University, Durham
COMMENT: BRUCE CHESON, Georgetown University, Washington DC
Flaxseed, a dietary supplement rich in lignan and omega-3 fatty acids, could help slow down the growth of prostate tumors. This came out of a phase II study presented at ASCO by Wendy Demark-Wahnefried of Duke University Medical Center in Durham, North Carolina. Derek Thorne heard more details from her in Chicago.
To listen this episode please go to 2007 ASCO Annual Meeting Daily News Podcasts.
Annual Meeting Daily News Podcasts - June 2nd, 2007
Ben Slotman
Roy Herbst
Prophylactic Cranial Irradiation: Fewer Brain Metastases, Longer Survival for Patients with Small Cell Lung Cancer
REFERENCE: ABSTRACT 4, ASCO Annual Meeting Chicago June 1-5, 2007
BEN SLOTMAN, VU Medical Center, Amsterdam
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
Any patient with small cell lung cancer responding to chemotherapy should now be offered prophylactic cranial irradiation, according to the findings of a study from the Netherlands reported to the Plenary Session of the ASCO meeting. Ben Slotman told Peter Goodwin about the results showing a two-thirds reduction of brain metastases and a near doubling of the number of patients surviving one year.
BEN SLOTMAN, VU Medical Center, Amsterdam
COMMENT: ROY HERBST, MD Anderson Cancer Center, Houston
Any patient with small cell lung cancer responding to chemotherapy should now be offered prophylactic cranial irradiation, according to the findings of a study from the Netherlands reported to the Plenary Session of the ASCO meeting. Ben Slotman told Peter Goodwin about the results showing a two-thirds reduction of brain metastases and a near doubling of the number of patients surviving one year.
Bayard Powell
Dean Bajorin
Arsenic Trioxide Improves Survival for Patients with Newly Diagnosed Acute Promyelocytic Leukemia
REFERENCE: ABSTRACT 2, ASCO Annual Meeting Chicago June 1-5, 2007
BAYARD POWELL, Wake Forest University, NC
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Newly diagnosed patients with acute promyelocytic leukemia benefit from having arsenic trioxide added to their standard all-trans retinoic acid and chemotherapy. This is according to a 500-patient study from North Carolina presented at the ASCO meeting. Bayard Powell told Sarah Maxwell his group’s latest findings from the study.
BAYARD POWELL, Wake Forest University, NC
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Newly diagnosed patients with acute promyelocytic leukemia benefit from having arsenic trioxide added to their standard all-trans retinoic acid and chemotherapy. This is according to a 500-patient study from North Carolina presented at the ASCO meeting. Bayard Powell told Sarah Maxwell his group’s latest findings from the study.
Ehab Atallah
Dean Bajorin
Dasatinib Activity in First Line Treatment For Patients with Chronic Myeloid Leukemia
REFERENCE: ABSTRACT 7005, ASCO Annual Meeting Chicago June 1-5, 2007
EHAB ATALLAH, MD Anderson Cancer Center, Houston
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Patients with chronic myeloid leukemia could soon have a new option for first line therapy. Dasatinib has outperformed imatinib in the laboratory, and is already approved for patients who fail imatinib. Now, it’s been tried in a phase II study involving 31 patients with chronic phase CML. Ehab Atallah of the MD Anderson Cancer Center in Houston discussed the latest data with Derek Thorne.
EHAB ATALLAH, MD Anderson Cancer Center, Houston
COMMENT: DEAN BAJORIN, Memorial Sloan-Kettering Cancer Center, New York
Patients with chronic myeloid leukemia could soon have a new option for first line therapy. Dasatinib has outperformed imatinib in the laboratory, and is already approved for patients who fail imatinib. Now, it’s been tried in a phase II study involving 31 patients with chronic phase CML. Ehab Atallah of the MD Anderson Cancer Center in Houston discussed the latest data with Derek Thorne.
Elias Jabbour
Nilotinib for Patients with Imatinib-Intolerant Chronic Myelogenous Leukemia in Chronic Phase
REFERENCE: ABSTRACT 7039, ASCO Annual Meeting Chicago June 1-5, 2007
ELIAS JABBOUR, MD Anderson Cancer Center, Houston
Patients with chronic myeloid leukemia who are intolerant to imatinib because of adverse events were mostly found to tolerate an alternative tyrosine kinase inhibitor, nilotinib. This was in a study from Texas looking at the use of nilotinib in patients who had failed first-line imatinib therapy either because of resistance or intolerance. ASCO 2007 Merit Award-winner Elias Jabbour told Peter Goodwin about the latest findings.
ELIAS JABBOUR, MD Anderson Cancer Center, Houston
Patients with chronic myeloid leukemia who are intolerant to imatinib because of adverse events were mostly found to tolerate an alternative tyrosine kinase inhibitor, nilotinib. This was in a study from Texas looking at the use of nilotinib in patients who had failed first-line imatinib therapy either because of resistance or intolerance. ASCO 2007 Merit Award-winner Elias Jabbour told Peter Goodwin about the latest findings.
Peter Wiernik
Lenalidomide Benefits Patients with Relapsed Refractory Non Hodgkin’s Lymphoma
REFERENCE: ABSTRACT 8052, ASCO Annual Meeting Chicago June 1-5, 2007
PETER WIERNIK, New York Medical College
Patients with aggressive relapsed, refractory non-Hodgkin’s lymphoma have responded to monotherapy with lenalidomide. That’s the finding of a small study reported to the ASCO meeting in Chicago. Peter Wiernik gave the details to Peter Goodwin at a poster session of the conference.
PETER WIERNIK, New York Medical College
Patients with aggressive relapsed, refractory non-Hodgkin’s lymphoma have responded to monotherapy with lenalidomide. That’s the finding of a small study reported to the ASCO meeting in Chicago. Peter Wiernik gave the details to Peter Goodwin at a poster session of the conference.
To listen this episode please go to 2007 ASCO Annual Meeting Daily News Podcasts.
Audio Journal of Oncology in Advance - June 1st, 2007 - reporting from: American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles">Audio Journal of Oncology in Advance - June 1st, 2007 - reporting from: American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
Lawrence Wickerham
Invasive Breast Cancer Chemoprevention Trials Assessed
REFERENCE: ABSTRACT Special Session; American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
LAWRENCE WICKERHAM, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
The best options for preventing invasive breast cancer among women at high risk were assessed at the AACR meeting. Lawrence Wickerham talked about the latest results from chemoprevention trials, which point to a need to rethink the way tamoxifen, raloxifene, and the aromatase inhibitors should be used. In Los Angeles he discussed his conclusions and recommendations with Karen Regester.
LAWRENCE WICKERHAM, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh
The best options for preventing invasive breast cancer among women at high risk were assessed at the AACR meeting. Lawrence Wickerham talked about the latest results from chemoprevention trials, which point to a need to rethink the way tamoxifen, raloxifene, and the aromatase inhibitors should be used. In Los Angeles he discussed his conclusions and recommendations with Karen Regester.
Stanley Gall
Five and a Half Year Results: Bivalent Human Papillomavirus Vaccine Success
REFERENCE: ABSTRACT 4900, American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
STANLEY GALL, University of Louisville, Kentucky
Latest data on the bivalent human papillomavirus vaccine for cervical cancer, showing continuing protection, were presented at the American Association for Cancer Research Annual Meeting in Los Angeles. With five and a half years of follow up, Stanley Gall discussed with Karen Regester the success of the vaccine.
STANLEY GALL, University of Louisville, Kentucky
Latest data on the bivalent human papillomavirus vaccine for cervical cancer, showing continuing protection, were presented at the American Association for Cancer Research Annual Meeting in Los Angeles. With five and a half years of follow up, Stanley Gall discussed with Karen Regester the success of the vaccine.
Andrew Lepisto
Theresa Whiteside
Autologous Vaccine: Benefit for Patients With Resectable Pancreatic Cancer?
REFERENCE: ABSTRACT 4896; American Association for Cancer Research Centennial Meeting, April 14-18, Los Angeles
ANDREW LEPISTO, University of Pittsburgh
THERESA WHITESIDE, University of Pittsburgh
An autologous vaccine for pancreatic cancer offers the hope of improving survival, and perhaps even cure, among patients who have resectable tumors. Peter Goodwin talked about the latest findings with Andrew Lepisto, and he asked Theresa Whiteside to give her assessment of the new data.
ANDREW LEPISTO, University of Pittsburgh
THERESA WHITESIDE, University of Pittsburgh
An autologous vaccine for pancreatic cancer offers the hope of improving survival, and perhaps even cure, among patients who have resectable tumors. Peter Goodwin talked about the latest findings with Andrew Lepisto, and he asked Theresa Whiteside to give her assessment of the new data.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Audio Journal of Oncology in Advance - May 15th, 2007 - reporting from: American Association for Cancer Research, April 14-18, 2007, Los Angeles, CA
Alberto Sobrero
Cetuximab With Irinotecan: Phase III Study Shows Benefit in Patients with Oxaliplatin-Refractory Colorectal Cancer
REFERENCE: ABSTRACT LB-2; AACR 2007, Los Angeles, Plenary Session
ALBERTO SOBRERO, Ospedale San Martino, Genoa
Cetuximab could become a mainstay of treatment for colorectal cancer along with fluorouracil, oxaliplatin, irinotecan, and bevacizumab, according to findings from the EPIC study presented at the AACR meeting in Los Angeles. 1,300 patients who had failed previous therapy with oxaliplatin were randomly assigned to receive irinotecan with or without cetuximab. The results point to a benefit of adding the molecular therapy, even though the effect was diluted because the protocol permitted crossover. Alberto Sobrero presented the data in Los Angeles, where he talked about it with Peter Goodwin.
ALBERTO SOBRERO, Ospedale San Martino, Genoa
Cetuximab could become a mainstay of treatment for colorectal cancer along with fluorouracil, oxaliplatin, irinotecan, and bevacizumab, according to findings from the EPIC study presented at the AACR meeting in Los Angeles. 1,300 patients who had failed previous therapy with oxaliplatin were randomly assigned to receive irinotecan with or without cetuximab. The results point to a benefit of adding the molecular therapy, even though the effect was diluted because the protocol permitted crossover. Alberto Sobrero presented the data in Los Angeles, where he talked about it with Peter Goodwin.
Derek Jonker
Cetuximab Monotherapy Benefits Patients With Refractory Metastatic Colorectal Cancer
REFERENCE: ABSTRACT LB-1, AACR 2007, Los Angeles: Plenary Session
DEREK JONKER, University of Ottawa
The molecularly targeted drug cetuximab has now proved capable of extending life when used as monotherapy among patients with refractory colorectal cancer. The CO17 phase III randomized trial of cetuximab versus best supportive care shows improvements in overall survival, progression-free survival, response rate, safety, and quality of life in a study with almost 600 patients who had metastatic colorectal cancer that had progressed despite all previous therapies. Derek Jonker told Karen Regester about their results with cetuximab monotherapy, which followed earlier promising work using the agent in combination with cytotoxic therapy.
DEREK JONKER, University of Ottawa
The molecularly targeted drug cetuximab has now proved capable of extending life when used as monotherapy among patients with refractory colorectal cancer. The CO17 phase III randomized trial of cetuximab versus best supportive care shows improvements in overall survival, progression-free survival, response rate, safety, and quality of life in a study with almost 600 patients who had metastatic colorectal cancer that had progressed despite all previous therapies. Derek Jonker told Karen Regester about their results with cetuximab monotherapy, which followed earlier promising work using the agent in combination with cytotoxic therapy.
Richard Goldberg
Cetuximab’s Role in Colorectal Cancer
REFERENCE: ABSTRACT LB-1 and LB-2; AACR 2007, Los Angeles Plenary Session, Monday 16th April, 2006
RICHARD GOLDBERG, University of North Carolina, Chapel Hill
Following the presentations from David Jonker and Alberto Sobrero at the AACR conference in Los Angeles, Richard Goldberg assessed the role of cetuximab in the treatment of metastatic, refractory colorectal cancer. He discussed the latest findings and his conclusions about their clinical implications with Peter Goodwin.
RICHARD GOLDBERG, University of North Carolina, Chapel Hill
Following the presentations from David Jonker and Alberto Sobrero at the AACR conference in Los Angeles, Richard Goldberg assessed the role of cetuximab in the treatment of metastatic, refractory colorectal cancer. He discussed the latest findings and his conclusions about their clinical implications with Peter Goodwin.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Audio Journal of Oncology in Advance - May 1st, 2007 - reporting from: American Association for Cancer Research 14-18 April, 2007 Los Angeles
Fritz Schröder
Opportunistic Prostate Screening May Not Save Lives!
REFERENCE: AACR 2007, Los Angeles
FRITZ SCHRÖDER, Erasmus University, Rotterdam
Though elective screening appears to have reduced the number of patients who die from prostate cancer in the United States, this has yet to be proven. A large European study is currently seeking to settle the matter, and one of the investigators, Fritz Schröder took part in a debate at the AACR entitled: Opportunistic Screening for Prostate Cancer: The Up and Down Sides of PSA Testing. Peter Goodwin talked with him about the dilemmas involved with prostate screening.
FRITZ SCHRÖDER, Erasmus University, Rotterdam
Though elective screening appears to have reduced the number of patients who die from prostate cancer in the United States, this has yet to be proven. A large European study is currently seeking to settle the matter, and one of the investigators, Fritz Schröder took part in a debate at the AACR entitled: Opportunistic Screening for Prostate Cancer: The Up and Down Sides of PSA Testing. Peter Goodwin talked with him about the dilemmas involved with prostate screening.
Peter Scardino
Debate on PSA Screening
REFERENCE: AACR 2007, Los Angeles
PETER SCARDINO, Memorial Sloan-Kettering Cancer Center, New York
The benefits of prostate cancer screening programs were questioned in a debate at the AACR conference in Los Angeles. Because the link between early detection and mortality is not simple, treatment risks could mean there is still an argument for watchful waiting in many patients. Peter Goodwin talked with Peter Scardino about the problems clinicians are facing in the age of the PSA test.
PETER SCARDINO, Memorial Sloan-Kettering Cancer Center, New York
The benefits of prostate cancer screening programs were questioned in a debate at the AACR conference in Los Angeles. Because the link between early detection and mortality is not simple, treatment risks could mean there is still an argument for watchful waiting in many patients. Peter Goodwin talked with Peter Scardino about the problems clinicians are facing in the age of the PSA test.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Audio Journal of Oncology in Advance - April 15th, 2007 - Bisphosphonates Recommended for Lung Cancer Bone Metastases
PETER HARPER, Guy’s Hospital, London
REFERENCE: “Management of Tumour and Treatment Related Symptoms” section, Perspectives in Lung Cancer, Seville
Bisphosphonates may be more suited for improving the outlook among patients with lung cancer who have bone metastases compared to palliative radiation and analgesics, according to Peter Harper, who assessed the data from recent studies for delegates at the Lung Cancer conference in Seville. He talked with Peter Goodwin.
Bisphosphonates may be more suited for improving the outlook among patients with lung cancer who have bone metastases compared to palliative radiation and analgesics, according to Peter Harper, who assessed the data from recent studies for delegates at the Lung Cancer conference in Seville. He talked with Peter Goodwin.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Audio Journal of Oncology in Advance - April 1st, 2007 - reporting From: Journal of Clinical Oncology, January 20th, 2007 & December 20, 2006
George Canellos
Robert Motzer
Hormone Replacement Therapy: Better Survival With Colorectal Cancer
REFERENCE: J Clin Oncol 24:5680-5686
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
Using postmenopausal estrogen replacement before the diagnosis of colorectal cancer was associated with better cancer-specific and overall mortality. This is the finding of a study by Jennifer Chan and colleagues from the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston. Peter Goodwin talked with George Canellos about the finding and its implications for therapy.
High-Dose Chemotherapy With Stem Cell Rescue: No Benefit as First-Line Therapy in Metastatic Germ Cell Tumors
REFERENCE: J Clin Oncol 25: 247-256
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
No advantage has emerged from high-dose chemotherapy as first-line therapy in patients with poor- and intermediate-risk metastatic germ cell tumors. A phase III randomized study comparing high-dose with standard-dose chemotherapy has been published in the Journal of Clinical Oncology by a group led by Robert Motzer of Memorial Sloan-Kettering Cancer Center in New York. George Canellos discusses these findings with Peter Goodwin and puts them into context with other recent related study findings.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Obesity, Car Travel, Climate Change: Linked?»
Phil Edwards, London School of Hyugiene and Tropical Medicine
LSHTM Audio News
Obesity Linked to Motor Transport And Climate Change
Peter Goodwin questions Phil Edwards of the London School of Hygiene and Tropical Medicine about "competition between stomachs and petrol tanks" discussed in a letter he and his colleague Ian Roberts have written to the medical magazine: The Lancet.Phil Edwards, London School of Hyugiene and Tropical Medicine
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
